Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06530719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Name: A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery — clinical trial record (NCT06530719)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorJin Ying

Started2024-07

View on ClinicalTrials.gov ↗

Record status

This record was last updated July 31, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery. The main questions it aims to answer is: whether EGFR-TKI is effective in the re-treatment of NSCLC after postoperative adjuvant targeted therapy relapse.

Trial Details

NCT Number	NCT06530719
Lead Sponsor	Jin Ying
Conditions	Lung Neoplasms, Lung Cancer, Nonsmall Cell
Enrollment	54 participants
Start Date	2024-07
Primary Completion	2026-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2024-07-31